Click to enlarge
Buy Opdivo (Nivolumab) $420.00 – $865.00
Back to products
Buy Tecentriq (Atezolizumab) $3,604.50

Buy Perjeta (Pertuzumab)

$1,470.00

Perjeta (pertuzumab) is a medication used for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer.

What is Perjeta (pertuzumab) for?

Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer

Compare
Add to wishlist
Category:
Description

How does Perjeta (pertuzumab) work?

Perjeta (pertuzumab) is used in combination with trastuzumab and docetaxel (other cancer medicines) for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

It is also used in combination with trastuzumab and chemotherapy as neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen for early breast cancer.

Is Perjeta (pertuzumab) approved?

Perjeta (pertuzumab) was approved for HER2 positive breast cancer in metastatic patients or as neoadjuvant therapy by:

  • FDA (USA) on June 12, 2012
  • EMA (EU) on March 4, 2013
  • TGA (AUS) on May 6, 2013
  • Health Canada on May 8, 2013
  • Medsafe (New Zealand) on July 18, 2013

How do I take Perjeta (pertuzumab)?

The standard dosage is:

  • Initial dose: 840 mg administered as a 60-minute intravenous infusion
  • Following infusions: 420 mg administered as a 30 to 60-minute intravenous infusion every 3 weeks.

Patients with metastatic breast cancer should be treated with pertuzumab and trastuzumab until disease progression or unmanageable toxicity.

Patients in neoadjuvant treatment of breast cancer should be administered pertuzumab every 3 weeks for 3 to 6 cycles before surgery.

Complete information about Perjeta (pertuzumab) dosage and administration can be found in the references section.

Note: Consult your treating doctor for personalised dosing.

Common side effects of Perjeta (pertuzumab)

The most common side effects with Perjeta given with trastuzumab and chemotherapy are:

  • diarrhoea
  • alopecia (hair loss)
  • nausea
  • neutropenia (low levels of neutrophils, a type of white blood cell important for fighting infections).

Serious side effects of Perjeta (pertuzumab)

The most common serious side effects include:

  • febrile neutropenia (low levels of neutrophils with fever)
  • serious diarrhoea
  • leucopenia (low white blood cell counts)
  • neutropenia.
Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Perjeta (Pertuzumab)”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

Shipping and delivery

All orders will only be dispatched once payment has been confirmed. Please fill in the shipping details and choose the payment method that suits you best.

-Shipping costs
You should always be clearly informed of the total price of your purchase, including delivery and other associated costs.
You must explicitly agree to any additional charges, for example if the merchant offers express delivery or gift wrapping.

-Damaged goods
The merchant is responsible for any damage caused to the product, from dispatch to receipt.
If you have purchased an item that does not conform in appearance or function to the advertised product, you have the right to request that it be repaired, replaced or, if neither of these is possible, refunded.

- Non-delivery
If you have not received the product within 30 days or by the agreed date, you must notify the merchant and allow a reasonable extension of time for delivery.
For example, if the merchant informs you of a one-week delay due to problems with his suppliers, it seems reasonable to allow him this extra week. If the trader still fails to deliver despite the extension, you have the right to terminate the contract and receive a prompt refund.

Related products

Compare
Quick view
Add to wishlist

Buy Darzalex (daratumumab)

$395.00 – $1,185.00
Select options
Darzalex (daratumumab) is a human CD38-directed monoclonal antibody used to treat multiple myeloma

Who is Darzalex (daratumumab) for?

Darzalex (daratumumab) is indicated for patients with:

  • newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.

  • multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.

  • multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (third-line treatment). For this indication, it is used in combination with pomalidomide and dexamethasone.

  • multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.

Compare
Quick view
Add to wishlist

Buy Ibrance (palbociclib)

$1,275.00 – $1,599.00
Select options

What is Ibrance (palbociclib) for?

Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (an hormonal therapy) as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.  

How does Ibrance (palbociclib) work?

 

Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.

Before a cell can divide, it has to go through four phases. The first phase is a growth phase (G1-phase), the second a synthesis phase (S-phase), the third another growth phase (G2-phase) and the last phase, where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Palbociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6)—two proteins that are involved in entering the S-phase[1].

Compare
Quick view
Add to wishlist

Buy Kadcyla (Trastuzumab Emtansine)

$1,665.00 – $2,669.00
Select options
Kadcyla (trastuzumab emtansine) is a cancer medicine that is used to treat advanced or metastatic HER2-positive breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane.
Compare
Quick view
Add to wishlist

Buy Keytruda (pembrolizumab)

$2,050.00
Select options
Keytruda (pembrolizumab) is a medication used for the treatment of advanced melanoma, metastatic nonsquamous NSCLC, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), recurrent classical Hodgkin Lymphoma (cHL), locally advanced or metastatic urothelial carcinoma, solid tumours having the biomarkers MSI-H or dMMR, recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, triple-negative breast cancer.
Compare
Quick view
Add to wishlist

Buy Opdivo (Nivolumab)

$420.00 – $865.00
Select options
Opdivo (nivolumab) is a medication used for the treatment of certain types of cancer.

What is Opdivo (nivolumab) for?

Opdivo (nivolumab) is indicated for the treatment of patients with:
  • metastatic melanoma as a single agent or in combination with ipilimumab
  • metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
  • advanced renal cell carcinoma who have received prior anti-angiogenic therapy
  • classical Hodgkin lymphoma that has relapsed or progressed after other treatments
  • recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
  • locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
  • microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
  • hepatocellular carcinoma in patients who have been previously treated with sorafenib
  • for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
Compare
Quick view
Add to wishlist

Buy Tecentriq (Atezolizumab)

$3,604.50
Select options
Tecentriq (atezolizumab) is a medication used for the treatment of locally advanced or metastatic urothelial carcinoma, for the treatment of metastatic non-small cell lung cancer (NSCLC), and for the treatment of advanced triple negative breast cancer (TNBC).
Compare
Quick view
Add to wishlist

Buy Vegzelma (Bevacizumab-adcd)

$375.00 – $1,125.00
Select options
Vegzelma (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), is a recombinant humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and inhibits the binding of VEGF to its receptors Flt-1 (VEGFR-1) and kinase insert domain receptor (VEGFR-2) on the surface of endothelial cells.
Vegzelma is indicated for the treatment of six types of cancer: metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.